Unicycive Therapeutics

Compare

727 Followers

UNCY Stock Chart & Stats

$4.75

-$0.03(-4.01%)

At close: Jan 08 4:00 PM EST

$4.75

-$0.03(-4.01%)

Day’s Range― - ―

52-Week Range$3.71 - $11.00

Previous CloseN/A

Volume1.16M

Average Volume (3M)450.50K

Market Cap

$90.60M

Enterprise Value$36.76M

Total Cash (Recent Filing)$22.33M

Total Debt (Recent Filing)$476.00K

Price to Earnings (P/E)―

Beta1.62

Next Earnings

Nov 18, 2025

EPS Estimate

-0.53

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding17,661,697

10 Day Avg. Volume334,820

30 Day Avg. Volume450,501

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)7.16

Price to Sales (P/S)0.00

P/FCF Ratio-1.86

Enterprise Value/Market Cap0.41

Enterprise Value/Revenue64.72

Enterprise Value/Gross Profit-328.24

Enterprise Value/Ebitda-0.93

Forecast

1Y Price Target

$36.60

Price Target Upside670.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company has a cash position of $42M, providing financial runway into 2027, which supports continued efforts towards drug approval.

Product InnovationOLC's nanoparticle formulation allows for a swallowable, non-chewable tablet with fewer, smaller pills per dose, addressing key patient adherence barriers.

Regulatory ProgressUnicycive plans to resubmit the New Drug Application for Oxylanthanum Carbonate, which could lead to FDA approval.

Bears Say

Unicycive Therapeutics News

Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025

Unicycive Therapeutics (UNCY) announced that it will present new oxylanthanum carbonate, OLC, data at the American Society of...

4d ago

UNCY

Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Unicycive Therapeutics (UNCY) to $22 from $9 and keeps a...

5d ago

UNCY

Unicycive provides update on meeting with FDA, resubmission of NDA for OLC

Unicycive Therapeutics (UNCY) announced an update from its meeting with the U.S. Food and Drug Administration, FDA, and...

6d ago

UNCY

Optimistic Buy Rating for Unicycive Therapeutics Driven by Promising Clinical Progress and Financial Stability

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Unicycive Therapeutics, with a price target of...

4d ago

UNCY

Unicycive Therapeutics Updates FDA Application for OLC

Unicycive Therapeutics ( ($UNCY) ) just unveiled an update. On October 28, 2025, Unicycive Therapeutics announced an update...

6d ago

UNCY

UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics

A class action lawsuit was filed against Unicycive Therapeutics ($UNCY) by Levi & Korsinsky on August 15, 2025. The plaintiffs (shareholders)...

1M ago

UNCY

Unicycive Therapeutics price target adjusted at Benchmark after reverse split

Benchmark raised the firm’s price target on Unicycive Therapeutics (UNCY) to $21 from $3 and keeps a Speculative...

2M ago

UNCY

Unicycive Faces Class Action Over FDA Misleading Claims

Unicycive Therapeutics, Inc., a biopharmaceutical company, is facing a class action lawsuit that could have significant implications for...

3M ago

UNCY

Unicycive Faces Securities Lawsuit Over Drug Claims

Unicycive Therapeutics ( ($UNCY) ) has provided an update. On August 15, 2025, Unicycive Therapeutics was named in...

3M ago

UNCY

Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

Unicycive Therapeutics (UNCY) announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for...

3M ago

UNCY

Unicycive Therapeutics Raises $16.3 Million in Stock Sale

Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. Unicycive Therapeutics, Inc. sold 3,549,846 shares of common stock...

3M ago

UNCY

Unicycive Therapeutics: Buy Rating Amid FDA Compliance Resolution and Strong Financial Position

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics, retaining the price target of...

3M ago

UNCY

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

“Our team has made great progress in the second quarter, and we have requested a Type A meeting...

3M ago

UNCY

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

Unicycive has requested a Type A meeting with the FDA to discuss resolution of the CRL received in...

3M ago

UNCY

UNCY FAQ

What was Unicycive Therapeutics’s price range in the past 12 months?

Unicycive Therapeutics lowest stock price was $3.71 and its highest was $11.00 in the past 12 months.

What is Unicycive Therapeutics’s market cap?

Unicycive Therapeutics’s market cap is $90.60M.

When is Unicycive Therapeutics’s upcoming earnings report date?

Unicycive Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 15 days.

How were Unicycive Therapeutics’s earnings last quarter?

Unicycive Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.683 by $0.163.

Is Unicycive Therapeutics overvalued?

According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unicycive Therapeutics pay dividends?

Unicycive Therapeutics does not currently pay dividends.

What is Unicycive Therapeutics’s EPS estimate?

Unicycive Therapeutics’s EPS estimate is -0.53.

How many shares outstanding does Unicycive Therapeutics have?

Unicycive Therapeutics has 17,661,697 shares outstanding.

What happened to Unicycive Therapeutics’s price movement after its last earnings report?

Unicycive Therapeutics reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.683. Following the earnings report the stock price went up 4.989%.

Which hedge fund is a major shareholder of Unicycive Therapeutics?

Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 0.

Unicycive Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-3987.11%

Trailing 12-Months

Asset Growth

-32.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Unicycive Therapeutics

Unicycive Therapeutics (UNCY) is a biopharmaceutical company focused on developing novel treatments for kidney diseases. The company operates within the healthcare sector, specifically targeting nephrology. Its core products include innovative therapies aimed at addressing unmet medical needs in patients suffering from chronic kidney diseases and related conditions.

Unicycive Therapeutics (UNCY) Earnings & Revenues

Historic Earnings Reports

UNCY Stock 12 Month Forecast

Average Price Target

$36.60

▲(670.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","61":"$61","16.75":"$16.75","31.5":"$31.5","46.25":"$46.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,16.75,31.5,46.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.46,8.732307692307693,13.004615384615384,17.27692307692308,21.54923076923077,25.821538461538463,30.093846153846158,34.36615384615385,38.63846153846154,42.91076923076923,47.183076923076925,51.45538461538462,55.727692307692315,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.46,6.932307692307692,9.404615384615385,11.876923076923077,14.349230769230768,16.821538461538463,19.293846153846154,21.76615384615385,24.23846153846154,26.71076923076923,29.183076923076925,31.655384615384616,34.12769230769231,{"y":36.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.46,5.7323076923076925,7.004615384615384,8.276923076923076,9.549230769230768,10.82153846153846,12.093846153846153,13.366153846153846,14.638461538461538,15.91076923076923,17.18307692307692,18.455384615384613,19.727692307692305,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.38,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >